Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | NNVC |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 24.4M |
| IPO Year | 1997 | N/A |
| Metric | LNG | NNVC |
|---|---|---|
| Price | $197.98 | $1.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $265.83 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 327.9K |
| Earning Date | 02-19-2026 | 02-13-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 14.15 | N/A |
| EPS | ★ 17.92 | N/A |
| Revenue | ★ $18,937,000,000.00 | N/A |
| Revenue This Year | $30.79 | N/A |
| Revenue Next Year | $13.52 | N/A |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | ★ 21.55 | N/A |
| 52 Week Low | $186.20 | $0.94 |
| 52 Week High | $257.65 | $2.23 |
| Indicator | LNG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 47.79 |
| Support Level | $188.13 | $1.20 |
| Resistance Level | $192.21 | $1.31 |
| Average True Range (ATR) | 3.21 | 0.07 |
| MACD | 1.39 | 0.00 |
| Stochastic Oscillator | 85.87 | 41.38 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.